Arkady Uryash, MD1, Harjit Gill, PhD2, Andrew Hoffmann, BSc3
1CEO, Parallel Biotechnologies LLC, Miami Beach, Florida; 2In-Vitro Laboratories, Burnaby, British Columbia, Canada; 3Ahof Biophysical Systems Inc., Burnaby, British Columbia, Canada.
Arkady Uryash, MD1, Harjit Gill, PhD2...
We present a prospective, double-blinded, randomized, controlled pilot study protocol to test whether tdVAS (50 Hz, 2mm), by 30-minute session directly following primary percutaneous coronary intervention, is feasible, safe, and may enhance...
We present a prospective, double-blinded, randomized, controlled pilot study protocol to test whether tdVAS (50 Hz, 2mm), by 30-minute session directly following primary percutaneous coronary intervention, is feasible, safe, and may enhance...
We present a prospective,...